Market Overview

Analyst: Why Diplomat Could Be Amazon's Ticket Into The Pharma Space

Share:
Analyst: Why Diplomat Could Be Amazon's Ticket Into The Pharma Space
Related AMZN
M&Ain't: Several Of The Year's Biggest Mergers Face Uncertain Future
Retail And Manufacturing Activity Continues At A Healthy Pace, Signaling Solid Freight Demand In The 3rd Quarter
An 8.1% Yield REIT That Benefits From The 'Amazon' Trend (Seeking Alpha)
Related DPLO
77 Biggest Movers From Yesterday
64 Stocks Moving In Tuesday's Mid-Day Session
Mariko Gordon Buys 5 New Stocks in —nd Quarter (GuruFocus)

Amazon.com, Inc. (NASDAQ: AMZN) confirmed its interest in the health care space earlier this year when it announced a health care partnership with J.P. Morgan Chase & Co. (NYSE: JPM) and Berkshire Hathaway Inc. (NYSE: BRK-A) (NYSE: BRK-B).

The M&A environment in the health care space has been heating up in anticipation of Amazon’s presence. Amazon could be among the buyers if it chooses to make a big splash in the pharmacy benefit manager market by acquiring Diplomat Pharmacy, Inc. (NYSE: DPLO), said Height Capital Markets analyst Andrea Harris. 

“In December, we wrote that the political and market headwinds facing pharmacy benefit managers make them attractive M&A targets, and that vertical integration among health care companies — driven by failed managed care mergers and propelled by corporate tax cuts — would lead standalone PBMs to combine with other parts of the health care delivery chain,” Harris said in a Tuesday note. 

At the time, Height identified Diplomat and Express Scripts Holding Company (NASDAQ: ESRX) as the two most likely buyout targets. CIGNA Corporation (NYSE: CI) recently announced a buyout bid for Express, which leaves Diplomat as the most strategic PMB buyout option, Harris said. 

“While a managed care organization or retail pharmacy would be the most straightforward potential purchaser, we have our eyes on serial disruptor Amazon,” the analyst said. 

If Amazon declines to pull the trigger on Diplomat, Harris said Humana Inc (NYSE: HUM) and Centene Corp (NYSE: CNC) would likely see Diplomat as an attractive buyout target.

Diplomat stock appears to be benefiting from the rumors: shares are up roughly 50 percent in the past year.

Related Links:

How Amazon's Ad Business Could Hit $22 Billion In 4 Years

Should Amazon Buy Wayfair? Loop Capital Makes The Case

Latest Ratings for AMZN

DateFirmActionFromTo
Jul 2018Morgan StanleyMaintainsOverweightOverweight
Jul 2018JefferiesMaintainsBuyBuy
Jul 2018Canaccord GenuityMaintainsBuyBuy

View More Analyst Ratings for AMZN
View the Latest Analyst Ratings

Posted-In: Andrea HarrisAnalyst Color News Health Care M&A Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (AMZN + BRK-A)

View Comments and Join the Discussion!

Where AI, Data, Blockchain Fit In The Trucking Industry

Craig-Hallum: Lumentum's Oclaro Purchase Could Trigger Further M&A In Optical Sector